Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
C4X Discovery
C4X Discovery
Activities:
Research & Development
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
KBI Biopharma extends contract with a big pharma giant after a successful FDA inspection
The contract has been renewed and extended until at least 2029, and will now include the purchase of two therapeutic products
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
New FAIRY viral assay could 'revolutionise' the response to future pandemics
The assay, which can detect the infectiousness of a virus in a matter of minutes, offers a quicker and cheaper alternative to the standard cell culture approach
New advice from BOLA and Labtex on cleaning and handling of PTFE products after use
The companies share: "Abrasive scouring agents may result in a milkiness of the vessels made of PFA and FEP. You may use all neutral detergents (pH 7). For higher contamination...
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Drug Delivery
C4XD signs $402 million licence with AstraZeneca
C4XD is eligible to receive upfront and pre-clinical payments of $16 million, plus development and commercial milestones, and tiered mid-single digit royalties
Research & Development
C4XD receives first milestone payment of €3 million from Sanofi
€3 million milestone payment triggered by preclinical progression in oral IL-17A inhibitor programme
Research & Development
C4X Discovery buys genetic platform provider Adorial for £1.7m
Adorial's mathematical tool Taxonomy3 has the potential to increase small molecule drug development success
Research & Development
C4X Discovery appoints Piers Morgan as Chief Executive
Succeeds Sam Williams who returns to Non-Executive Director role
Research & Development
UK biotechs win Biomedical Catalyst funding of almost £100m
Thirty-three UK companies have received business-led awards
Subscribe now